{
  "docId": "019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "docSlug": "2cfade3d34acc49c8d5f05063b654956",
  "documentTitle": "ATAI | Investor Presentation Deck | 49 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 49,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a timeline framework to contrast past performance with future expectations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-19a4-704e-b5bc-b8f4ae0c7550/8",
  "deckHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "deckJsonHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550.json",
  "deckAnchorHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Anticipated catalysts across 2022, 2023 & 2024",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c89d2e5-0569-4384-aa3c-c37fe3087b08",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "framework",
      "text": "Milestone highlights in 2021",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31243755-d843-4887-ba26-8e3376d14bf4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "Positive topline results in Phase 2b trial of COMP360 in TRD patients; Successful outcomes of Phase 2a proof-of-mechanism trial of RL-007 in CIAS patients; Successful outcomes of Phase 1 trial of PCN-101; Collaboration agreement with Otsuka Pharma; Acquired or incubated 6 new platform companies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75508820-9ca0-46ab-82e8-80b1bb8825f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "We will build on recent success by delivering several meaningful R&D catalysts anticipated across our key programs in 2022, 2023 & 2024",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ddd0a550-fe92-45ee-9583-4cf34c72acf6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "2eef5af0-e447-497a-8088-a86ba321a2ac",
      "evidence": "Chronological presentation of past achievements and future milestones.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}